A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis

Trial Profile

A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs KZR 616 (Primary)
  • Indications Lupus nephritis; Systemic lupus erythematosus
  • Focus Adverse reactions
  • Sponsors Kezar Life Sciences
  • Most Recent Events

    • 07 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 10 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top